据彭博新闻社报导，辉瑞在与诺和诺德的竞购战中提高了对美塞拉的报价

路透中文

2025/11/08

据彭博新闻社报导，<a href="https://laohu8.com/S/PFE">辉瑞</a>在与<a href="https://laohu8.com/S/NVO">诺和诺德</a>的竞购战中提高了对美塞拉的报价

路透11月8日 - 据彭博新闻社周五报导，辉瑞PFE.N已向肥胖症药物开发商美塞拉MTSR.O提交了一份更诱人的出价，因为辉瑞与竞争对手诺和诺德NOVOb.CO的争斗正在升级。

彭博社援引熟悉内情的人士的话报导说，辉瑞的新报价提高了早些时候提出的每股86.20美元（包括里程碑付款）的建议。

路透无法立即核实彭博社的报导。

就在总部位于纽约的辉瑞公司于周三晚些时候与这家丹麦制药商之前提出的100亿美元收购方案相匹配后数小时，诺和诺德于周四提高了对这家美国生物技术公司的收购报价 (link)。

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2581938858"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581938858\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581938858?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-08 08:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581938858","market":"us","top_or_hot":-1,"title":"据彭博新闻社报导，辉瑞在与诺和诺德的竞购战中提高了对美塞拉的报价","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>据彭博新闻社报导，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>在与<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的竞购战中提高了对美塞拉的报价</title></head><body><p>\n<span>路透11月8日</span><span> - </span>据彭博新闻社周五报导，辉瑞<span>PFE.N</span>已向肥胖症药物开发商美塞拉<span>MTSR.O</span>提交了一份更诱人的出价，因为辉瑞与竞争对手诺和诺德<span>NOVOb.CO</span>的争斗正在升级。</p><p>彭博社援引熟悉内情的人士的话报导说，辉瑞的新报价提高了早些时候提出的每股86.20美元（包括里程碑付款）的建议。</p><p>路透无法立即核实彭博社的报导。</p><p>就在总部位于纽约的辉瑞公司于周三晚些时候与这家丹麦制药商之前提出的100亿美元收购方案相匹配后数小时，诺和诺德于周四提高了对这家美国<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司的收购报价 (<span>link</span>)。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>据彭博新闻社报导，辉瑞在与诺和诺德的竞购战中提高了对美塞拉的报价</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n据彭博新闻社报导，辉瑞在与诺和诺德的竞购战中提高了对美塞拉的报价\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-11-08 08:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>据彭博新闻社报导，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>在与<a href=\"https://laohu8.com/S/NVO\">诺和诺德</a>的竞购战中提高了对美塞拉的报价</title></head><body><p>\n<span>路透11月8日</span><span> - </span>据彭博新闻社周五报导，辉瑞<span>PFE.N</span>已向肥胖症药物开发商美塞拉<span>MTSR.O</span>提交了一份更诱人的出价，因为辉瑞与竞争对手诺和诺德<span>NOVOb.CO</span>的争斗正在升级。</p><p>彭博社援引熟悉内情的人士的话报导说，辉瑞的新报价提高了早些时候提出的每股86.20美元（包括里程碑付款）的建议。</p><p>路透无法立即核实彭博社的报导。</p><p>就在总部位于纽约的辉瑞公司于周三晚些时候与这家丹麦制药商之前提出的100亿美元收购方案相匹配后数小时，诺和诺德于周四提高了对这家美国<a href=\"https://laohu8.com/S/000504\">生物</a>技术公司的收购报价 (<span>link</span>)。</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0321505439.SGD","symbol_name":"Schroder ISF Global Dividend Maximiser A Acc SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251108:nL4T3WK00V:1","article_id":"2581938858","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581938858","pubTimestamp":1762563485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"路透11月8日 - 据彭博新闻社周五报导，辉瑞PFE.N已向肥胖症药物开发商美塞拉MTSR.O提交了一份更诱人的出价，因为辉瑞与竞争对手诺和诺德NOVOb.CO的争斗正在升级。彭博社援引熟悉内情的人士的话报导说，辉瑞的新报价提高了早些时候提出的每股86.20美元的建议。路透无法立即核实彭博社的报导。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4139":"生物科技","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","BK4585":"ETF&股票定投概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999001176.USD":"United Global Healthcare Acc USD","BK4592":"伊斯兰概念","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999002232.USD":"Allianz Global High Payout USD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","BK4007":"制药","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","MTSR":"Metsera Inc.","BK4581":"高盛持仓","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","PFE":"辉瑞","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4534":"瑞士信贷持仓","LU0234572021.USD":"高盛美国核心股票组合Acc"},"translate_title":"According to Bloomberg News, Pfizer raises its offer for Mesera in bidding war with Novo Nordisk","themeId":"14a71f61cb92b2ae51e4a7c3aa48f71f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"MTSR":0.9},"content_text":"据彭博新闻社报导，辉瑞在与诺和诺德的竞购战中提高了对美塞拉的报价\n路透11月8日 - 据彭博新闻社周五报导，辉瑞PFE.N已向肥胖症药物开发商美塞拉MTSR.O提交了一份更诱人的出价，因为辉瑞与竞争对手诺和诺德NOVOb.CO的争斗正在升级。彭博社援引熟悉内情的人士的话报导说，辉瑞的新报价提高了早些时候提出的每股86.20美元（包括里程碑付款）的建议。路透无法立即核实彭博社的报导。就在总部位于纽约的辉瑞公司于周三晚些时候与这家丹麦制药商之前提出的100亿美元收购方案相匹配后数小时，诺和诺德于周四提高了对这家美国生物技术公司的收购报价 (link)。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}